Pediatrix Medical Group (MD) stock surged 8.43% in pre-market trading on Thursday, following the release of its better-than-expected fourth quarter 2024 results and an upbeat outlook for 2025.
For the fourth quarter, the company reported adjusted earnings per share of $0.51, beating the consensus estimate of $0.37. Revenue of $502.4 million also topped expectations of $486.2 million, driven by an 8.7% increase in same-unit revenue.
Looking ahead, Pediatrix anticipates its 2025 Adjusted EBITDA to range between $215 million and $235 million, reflecting continued growth and operational efficiency efforts. The company expects to benefit from its recent portfolio restructuring and overhead expense reductions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.